• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by PharmaCyte Biotech Inc.

    12/4/24 5:27:05 PM ET
    $PMCB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PMCB alert in real time by email
    S-8 1 pharmacyte_s8.htm REGISTRATION STATEMENT

     

    As filed with the Securities and Exchange Commission on December 4, 2024

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PHARMACYTE BIOTECH, INC.

    (Exact name of registrant as specified in its charter)

     

     
       
    Nevada 62-1772151

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

       

    3960 Howard Hughes Parkway, Suite 500

    Las Vegas, Nevada

    89169
    (Address of Principal Executive Offices) (Zip Code)

     

    PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan

    PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan

    (Full titles of the plans)

     

    Joshua N. Silverman

    Interim Chief Executive Officer, Interim President and Interim Chairman of the Board

    PharmaCyte Biotech, Inc.

    3960 Howard Hughes Parkway, Suite 500

    Las Vegas, Nevada

    Telephone: (917) 595-2850

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Kenneth R. Koch

    Daniel A. Bagliebter

    Jeffrey D. Cohan

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    919 Third Avenue

    New York, New York 10022

    212-935-3000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

       

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for by Part I of Form S-8 is omitted from this Registration Statement in accordance with Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     2 

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    PharmaCyte Biotech, Inc. (the “Registrant”) hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

     

    ·the Registrant’s Annual Report on Form 10-K for the year ended April 30, 2024, filed with the SEC on August 13, 2024;
       
    ·the Registrant’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2024, filed with the SEC on September 17, 2024; and
       
    ·the description of the Registrant’s Common Stock set forth in a registration statement on Form 8-A, filed with the SEC on August 2, 2021, including any further amendments thereto or reports filed for the purposes of updating this description.

     

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant’s directors and officers are indemnified as permitted by the Registrant’s Articles of Incorporation, as amended (the “Articles of Incorporation”), its bylaws, as amended (the “Bylaws”) and the Nevada Revised Statutes (“NRS”). The Registrant believes that the indemnity and limitation of liability provisions contained in the indemnification agreements with its officers and directors are necessary to attract and retain qualified persons for those positions. No pending material litigation or proceeding involving the Registrant’s directors, executive officers, employees or other agents as to which indemnification is being sought exists, and the Registrant is not aware of any pending or threatened material litigation that may result in claims for indemnification by any of its directors or executive officers.

     

    The following is a summary of the relevant provisions in the Articles of Incorporation, Bylaws, and Nevada law with regard to limitation of liability and indemnification of the Registrant’s directors and officers. The full provisions are contained in the NRS and such documents.

     

     

     

     3 

     

     

    Limitation of Liability

     

    The NRS provide that an officer or director of a Nevada corporation will not be liable for acts or omissions unless:

     

    ·the presumption that the officer or director acted in good faith, on an informed basis and with a view to the interests of the corporation is rebutted;
       
    ·it is proven that the officer's or director's acts or omissions constituted a breach of fiduciary duties; and
       
    ·it is proven that such breach involved intentional misconduct, fraud, or a knowing violation of law.

     

    Indemnification

     

    The indemnification agreements that the Registrant has with our officers and directors provide for their indemnification to the fullest extent permitted by Nevada law. The Bylaws and the NRS provide that a corporation may indemnify directors and officers who were or are a party or are threatened to be made a party to any threatened, pending, or completed action, lawsuit, or proceeding, whether civil, criminal, administrative, or investigative, including an action by or in the right of the corporation, by reason of the fact that such person is or was a director or officer of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses, including attorneys’ fees, judgments, fines, and amounts paid in settlement actually and reasonably incurred by such person in connection with the action, lawsuit, or proceeding as long as such person:

     

    ·is not liable under Section 78.138 of the NRS, i.e., exercised his or her powers as a director or officer of the corporation in good faith and with a view to the interests of the corporation; and
       
    ·acted in good faith and in a manner that such person reasonably believed to be in or not opposed to the best interest of the corporation, or, with respect to any criminal action or proceeding, had reasonable cause to believe his conduct was unlawful.
       
    ·the corporation is required to indemnify any director or officer against expenses, including attorneys’ fees, incurred by such person who has been successful on the merits or otherwise in defense of any action, suit, or proceeding.

     

    The Registrant will advance expenses of any director or officer incurred in defending any civil or criminal action, lawsuit, or proceeding and such director or officer must repay the amount advanced if it is ultimately determined by a court of competent jurisdiction that the director or officer is not entitled to be indemnified by the corporation.

     

    The Registrant has been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against these types of liabilities, other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person in the successful defense of any action, lawsuit or proceeding, is asserted by a director, officer or controlling person in connection with the securities being registered, the Registrant will (unless in the opinion of its counsel, the matter has been settled by controlling precedent) submit to a court of appropriate jurisdiction, the question whether indemnification by the Registrant is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. The legal process relating to this matter if it were to occur is likely to be very costly and may result in us receiving negative publicity, both of which are likely to materially reduce the market and price for our shares.

     

    The Registrant maintains a director and officer insurance policy that covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

     

     

     

     4 

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The exhibits to this Registration Statement are listed below:

     

            Incorporated by Reference
    Exhibit
    Number
      Description   Schedule
    Form
      File
    Number
      Exhibit   Filing Date
                         
    5.1*   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.                
                         
    23.1*   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).                
                         
    23.2*   Consent of Marcum LLP.                
                         
    23.3*   Consent of Armanino LLP.                
                         
    24.1*   Power of Attorney (included on the signature page of this Registration Statement).                
                         
    99.1   PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan.   10-K   001-40699   10.42   July 28, 2022
                         
    99.2   PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan.   DEF 14A   001-40699   Appendix A   November 25, 2022
                         
    107*   Filing Fee Table.                
                         
    *   Filed herewith.                

     

     

     

     5 

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     6 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Las Vegas, Nevada, on the 4th day of December, 2024.

     

      PHARMACYTE BIOTECH, INC.
         
      By:

    /s/ Joshua N. Silverman

        Joshua N. Silverman
        Interim Chief Executive Officer and Interim President

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joshua N. Silverman and Carlos A. Trujillo and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
         

    /s/ Joshua N. Silverman

    Joshua N. Silverman

     

    Interim Chief Executive Officer and Interim President

    (Principal Executive Officer)

      December 4, 2024
         

    /s/ Carlos A. Trujillo

    Carlos A. Trujillo

     

    Chief Financial Officer

    (Principal Accounting Officer and Principal Financial Officer)

      December 4, 2024
         

    /s/ Michael Abecassis

    Dr. Michael Abecassis

      Director   December 4, 2024
         

    /s/ Jonathan L. Schechter

    Jonathan L. Schechter

      Director   December 4, 2024
         

    /s/ Wayne R. Walker

    Wayne R. Walker

      Director   December 4, 2024
         

    /s/ Robert Weinstein

    Robert Weinstein

      Director   December 4, 2024
         

     

     

     

     7 

     

    Get the next $PMCB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PMCB

    DatePrice TargetRatingAnalyst
    11/8/2021Neutral
    HC Wainwright & Co.
    More analyst ratings

    $PMCB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

      Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FD

      5/21/24 9:00:00 AM ET
      $MYMD
      $PMCB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • MyMD Pharmaceuticals Secures Strategic Investments

      Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD

      5/21/24 9:00:00 AM ET
      $MYMD
      $PMCB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

      New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv

      11/15/23 8:30:00 AM ET
      $FEMY
      $PMCB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PMCB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on PharmaCyte Biotech

      HC Wainwright & Co. initiated coverage of PharmaCyte Biotech with a rating of Neutral

      11/8/21 6:05:27 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weinstein Robert

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:59:12 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walker Wayne Remell

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:58:59 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Schechter Jonathan

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:58:49 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    SEC Filings

    See more
    • PharmaCyte Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      4/24/25 4:47:19 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by PharmaCyte Biotech Inc.

      10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      3/17/25 5:22:56 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by PharmaCyte Biotech Inc.

      DEFA14A - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      3/10/25 4:18:48 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Leadership Updates

    Live Leadership Updates

    See more
    • Oblong Appoints Two New Directors to its Board

      Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

      5/30/23 8:00:00 AM ET
      $OBLG
      $PMCB
      $PTPI
      $SNPX
      Computer Software: Programming Data Processing
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

      Company Appoints Five New Independent Directors to Reconstituted Board PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCyte's outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois' director designees to PharmaCyte's reconstituted Board of Directors. Pursuant to the Agreement, Iroquois' director designees, Jonathan L. Schechter and Jo

      8/15/22 8:30:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

      PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its preliminary unaudited financial results for fiscal year ended April 30, 2022. Cash Position PharmaCyte had $85.4 million in cash and cash equivalents as of April 30, 2022. Preliminary (Unaudited) 2022 Fiscal Year End Financial Results PharmaCyte expects to report operating expenses of approximately $4.4 million, compared to $3.6 million in the prior fiscal year. This increase is primarily due to expenses associated with PharmaCyte listing on Nasdaq an

      7/11/22 8:30:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Financials

    Live finance-specific insights

    See more
    • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

      New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv

      11/15/23 8:30:00 AM ET
      $FEMY
      $PMCB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

      Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Company's Dismal Efforts to Communicate with Shareholders Including its Failure to Hold Quarterly Conference Calls Questions the Board and Management's Alignment with Shareholders Given Minimal Stock Ownership and Failure to Purchase Shares in the Open Market Calls on the Company to Actively Enlist Shareholder Participation in a Process to Refresh a Majority of the Directors on the Board with Highly Qualified Candidates to Fill Gaps in the Existing Leadership's Skillset and Bring Fresh Perspecti

      5/11/22 9:00:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PharmaCyte Biotech Inc.

      SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      11/13/24 11:19:35 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by PharmaCyte Biotech Inc.

      SC 13G - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      2/14/24 3:38:38 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by PharmaCyte Biotech Inc. (Amendment)

      SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      2/6/24 9:56:28 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care